Peaches Biotech Group is a Spanish company focused on the creation of innovative drugs based on advanced cell therapies, particularly secretomes (cell signaling molecules) and T-lymphocyte re-educatio
n. Their core activities include research and development of proprietary technologies like PRS® (Selective Rich Plasma) for regenerative purposes and opT® cells for cancer treatment. The company collaborates with hospitals and research centers, operates a Bioincubator at the University Hospital of Fuenlabrada, and has partnered to create the first GMP-certified plant (Histokine) in Spain for secretome production. Peaches Biotech aims to develop cost-effective, advanced therapeutic options to i
